Review articlePublished 2020
Development of an Extended-Release Exenatide Once a Week Depot Formulation
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Bydureon™, the Exenatide extended-release formulation depot, has been approved in the USA for once weekly treatment for type 2 diabetes mellitus. Exenatide is a synthetic version of exendin-4 with biological properties similar to human glucagon-like peptide-1 (GLP-1) agonist. Evonink Industries at Birmingham - Alabama, USA developed the process based on available reported information to produce Exenatide loaded microparticles that demonstrate a similar in vivo release profile compared to the reference listed drug (RLD). The drug loading, initial burst and other characteristics of the exenatide loaded microparticles are in the range of RLD. Surface characterization by scanning electron microscopy (SEM) of the Evonik produced microparticle visually matches with RLD.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalSystematic Reviews in Pharmacy
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Jabar A Faraj”
- BylineArticles whose byline prints “Shaimaa M. Mohammed”
- BylineArticles whose byline prints “Khulood M. Alsaraf”
- BylineArticles whose byline prints “Ihab I. Alkhalifa”
- BylineArticles whose byline prints “Kadum A. Al Shareffi”
- BylineArticles whose byline prints “K. Burton.”